All In Biotech

Drug Trial Radar · NCT04136756

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 7, 2019

Primary completion

Apr 24, 2023

Study completion Apr 24, 2023

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.

Conditions

  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Indolent Non-Hodgkin Lymphoma

Interventions

  • NKTR-255Drug

    NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability

  • NKTR-255 Q21Drug

    NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability

  • RituximabDrug

    Rituximab administered intravenously at specified dose on specified days

  • DaratumumabDrug

    Daratumumab administered subcutaneously at specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agentTime frame: Through study completion, an expected average of 6 months
  2. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with daratumumab SCTime frame: Through study completion, an expected average of 1 year
  3. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with rituximabTime frame: Through study completion, an expected average of 1 year
  4. Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 as a single agentTime frame: Through study completion, an expected average of 6 months
  5. Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with daratumumab SCTime frame: Through study completion, an expected average of 1 year
  6. Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with rituximabTime frame: Through study completion, an expected average of 1 year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Western Regional Medical Center - CTCA

    Goodyear, Arizona

  • City of Hope

    Duarte, California

  • University of California, San Francisco

    San Francisco, California

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • New York Medical College

    Valhalla, New York

  • Duke University Health System

    Durham, North Carolina

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.